Erste Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Erste Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.27M	Buy	+25,000	New	+$1.06M	0.01%	432

Other funds holding ELVN

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Erste Asset Management's ELVN Position: Q2 2026 in Review

Erste Asset Management opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 25,000 shares worth $1.27M. The stake represents 0.01% of the portfolio and ranks #432 among its holdings.

21 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

Erste Asset Management held 25,000 shares of Enliven Therapeutics worth $1.27M as of Q2 2026.
Enliven Therapeutics was a new Erste Asset Management position in Q2 2026.
Enliven Therapeutics made up 0.01% of Erste Asset Management's portfolio in Q2 2026, its #432 holding.
21 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.